NL-OMON49589已完成不适用
Butyrate/hexanoate-enriched triglycerides for metabolic health - Butyrate/hexanoate in metabolic health
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Overweight/obese men (BMI >= 25 kg/m2 and <= 34.9 kg/m2);
- •- Aged 40 - 70 years;
- •- Caucasian;
- •- Normal blood pressure (systolic blood pressure 100-140mmHg, diastolic blood
- •pressure 60-90 mmHg);
- •- Weight stable for at least 3 months (± 2 kg).
排除标准
- •- Type 2 diabetes mellitus (defined as fasting plasma glucose >= 7.1 mmol/L)
- •- Gastroenterological diseases or abdominal surgery (gallbladder removal and
- •appendix removal are allowed)
- •- Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a
- •life expectancy shorter than 5 years;
- •- Lactose intolerance or other disorders that affect digestion (such as celiac
- •- Abuse of products; alcohol and drugs, excessive nicotine use defined as >20
- •cigarettes per day; and excessive alcohol use defined as (> 15 units/week)
- •- Plans to lose weight or following of a hypocaloric diet in the following
- •three months;
- •- Regular supplementation of pre- or probiotic products (for example Yakult,
- •Activia), use of pre- or probiotics 3 months prior to the start of the study;
- •- Intensive exercise training more than three hours a week;
- •- Use of any medication that influences glucose or fat metabolism and
- •inflammation (i.e. betablockers, corticosteroids, statins or NSAIDs);
- •- Regular use of laxation products in 3 months prior start of study or during
- •study period;
- •- Use of antibiotics in the last three months (antibiotics use can alter
- •substantially the gut microbiota composition).
- •- Follow a vegan diet or vegetarian diet.
研究者
相似试验
已完成
不适用
Butyrate/Hexanoate in Metabolic HealthMetabolic DiseaseNCT04662411Maastricht University Medical Center14
进行中（未招募）
不适用
A double-blind, placebo-controlled, intervention trial comparing the triglyceride-lowering effect of omega-3 polyunsaturated fatty acids, as either ethyl ester or triglycerides in patients with moderately elevated triglyceride levels in the blood in non fasting state.MedDRA version: 15.0Level: LLTClassification code 10071235Term: Combined hyperlipidemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 15.0Level: LLTClassification code 10060754Term: Type IV hyperlipidemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHypertriglyceridemiaEUCTR2012-003029-11-DKSteen Stender
招募中
3 期
Ketogenic diet along with high-dose ascorbic acid in triple-negative breast cancerTriple negative breast cancer.Malignant neoplasm of breastIRCT20161022030424N11Tabriz University of Medical Sciences240
进行中（未招募）
不适用
Medium-chain fat supplementation and growth in infants with biliary atresia: a feasibility studyBiliary atresiaDigestive SystemISRCTN81936667King's College London30
招募中
2 期
Confirmation of effects of medium chain triglyceride therapy for citrin deficiencycitrin deficiencyEndocrinology and Metabolism, PediatricsD006111JPRN-jRCTs041190017Mitsui Tetsuo50